Dentsply Sirona
XRAY
$11.01
+2.13%
DENTSPLY SIRONA Inc. is a global leader in the design, development, and manufacturing of dental equipment and consumables, operating within the Medical Instruments & Supplies industry. The company's distinct identity stems from its comprehensive portfolio, which spans dental consumables, lab products, CAD/CAM technology, imaging systems, and specialty products, positioning it as a one-stop-shop for dental professionals. The current investor narrative is dominated by a challenging turnaround story, as the company grapples with inconsistent profitability and significant share price weakness, with recent financial results and analyst actions reflecting ongoing debates about its ability to stabilize operations and return to sustainable growth.…
XRAY
Dentsply Sirona
$11.01
Investment Opinion: Should I buy XRAY Today?
Rating: Hold. The core thesis is that XRAY is a deeply troubled company trading at a crisis-level valuation, where the potential reward of a successful turnaround is offset by the high probability of continued fundamental deterioration and the stock's complete lack of positive momentum.
Supporting this view are four key data points: 1) The severely discounted valuation (PS of 0.62, EV/Sales of 1.11) reflects extreme pessimism. 2) While Q4 revenue grew 6.19% YoY, profitability remains deeply negative with a -16.25% net margin. 3) Positive TTM free cash flow of $104 million and a current ratio of 1.51 provide near-term liquidity, but the high 5.62% dividend yield is at risk if earnings don't recover. 4) Analyst sentiment is cautious but not panicked, with a mix of Buy and Hold ratings, indicating a wait-and-see approach rather than conviction.
The thesis would upgrade to a speculative Buy if the company reports two consecutive quarters of expanding gross margins (back above 50%) and a clear path to sustained positive EBITDA, signaling a turnaround is underway. It would downgrade to a Sell if quarterly free cash flow turns negative, the dividend is cut, or the stock decisively breaks below the $9.41 support level on worsening fundamentals. Relative to its own distressed history and the severity of its operational challenges, the stock is fairly valued in its current state—the discount is warranted, not necessarily an opportunity.
Sign up to view all
XRAY 12-Month Price Forecast
XRAY is a classic 'show me' story trapped in a deep-value vortex. The stock price reflects a crisis, but the fundamental data does not yet provide clear evidence that a recovery is imminent. The positive free cash flow and lack of analyst Sell ratings prevent an outright bearish stance, but the severe profitability issues and negative momentum preclude bullishness. The stance would upgrade to cautiously bullish on two consecutive quarters of gross margin expansion and positive EBITDA. It would turn bearish on a breakdown below $9.41 support coupled with a negative free cash flow quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dentsply Sirona's 12-month outlook, with a consensus price target around $14.31 and implied upside of +30.0% versus the current price.
Average Target
$14.31
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$9 - $14
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is not a widely followed large-cap stock, which can contribute to higher volatility and less efficient price discovery. The consensus sentiment appears mixed, as institutional ratings show a distribution including Buy (Barrington Research, B of A Securities, UBS), Neutral/Equal Weight (Mizuho, Baird, Evercore ISI, Wells Fargo), and no outright Sell ratings, suggesting analysts are cautiously awaiting evidence of a turnaround. Specific price targets and implied upside are not available in the provided data, preventing calculation of a target range; the absence of this key consensus data further underscores the uncertainty and limited institutional conviction surrounding the stock's near-term prospects.
Bulls vs Bears: XRAY Investment Factors
The bear case currently holds stronger evidence, anchored by a severe profitability crisis, a persistent technical downtrend, and high financial leverage. The stock's deep valuation discount is a bull argument, but it is a reflection of these fundamental failures rather than a clear margin of safety. The single most important tension in the investment debate is whether the company's positive free cash flow and recent EBITDA improvement represent the first signs of a credible operational turnaround that can halt the margin erosion, or if they are merely temporary respites in a continued downward spiral toward deeper losses and potential financial distress.
Bullish
- Deeply Discounted Valuation: The stock trades at a Price-to-Sales ratio of 0.62 and an EV/Sales of 1.11, representing a severe discount to its revenue base and near the bottom of its multi-year historical range. This extreme pessimism, with the stock only 10.7% above its 52-week low, could present a deep-value opportunity if the company demonstrates any credible operational turnaround.
- Positive Free Cash Flow Generation: Despite net losses, the company generated $104 million in TTM free cash flow and $60 million in Q4 2025. This provides crucial internal funding for its high 5.62% dividend yield and operations, offering a margin of safety and reducing near-term liquidity risk.
- Revenue Growth in Key Segment: Q4 2025 revenue grew 6.19% YoY to $961 million, driven by the Technologies & Equipment segment ($548M). This indicates underlying demand for its core products persists despite the company's profitability challenges.
- Analyst Sentiment Lacks Outright Sells: Institutional ratings include several Buy and Hold/Neutral ratings, with no outright Sell recommendations among the 5 covering analysts. This suggests professional skepticism is balanced with cautious optimism for a potential recovery.
Bearish
- Severe and Sustained Profitability Crisis: The company reported a Q4 2025 net loss of -$146 million, a TTM net margin of -16.25%, and a negative ROE of -44.63%. Gross margin compressed to 46.1% in Q4 from 52.4% in Q2, indicating an inability to translate revenue into earnings.
- Persistent Technical Downtrend: The stock is down 38.63% over the past year and 22.45% over the past three months, severely underperforming the SPY. It trades just above its 52-week low of $9.41, reflecting a complete lack of investor confidence and momentum.
- High Financial Leverage: A debt-to-equity ratio of 1.84 indicates significant financial risk, especially for a company with volatile and negative earnings. This leverage amplifies the downside risk if the turnaround fails to materialize.
- Inconsistent Quarterly Performance: Revenue growth is choppy, with Q4 revenue of $961M down sequentially from $936M in Q2. Profitability is wildly volatile, swinging from a $20M net income in Q1 2025 to a -$427M loss in Q3, making forecasting and valuation extremely difficult.
XRAY Technical Analysis
The stock is entrenched in a pronounced and sustained downtrend, evidenced by a 1-year price change of -38.63% and a 6-month decline of -12.18%. With a current price of $9.88, it is trading at just 10.7% above its 52-week low of $9.41, positioning it near the absolute bottom of its annual range; this suggests the market is pricing in severe fundamental distress, though it may also attract deep-value investors if a stabilization catalyst emerges. Recent momentum remains decisively negative, with the stock down -13.10% over the past month and -22.45% over the past three months, significantly underperforming the SPY, which gained 4.6% and 12.6% over the same periods, as reflected in the severe relative strength readings of -17.70 and -35.05, respectively. Key technical levels are clearly defined, with immediate support at the 52-week low of $9.41 and resistance far above at the 52-week high of $17.09; a decisive breakdown below $9.41 would signal a new leg down, while a recovery above the recent high of $14.68 (from February 27) is needed to suggest any meaningful trend reversal. The stock's beta of 0.941 indicates its volatility is roughly in line with the broader market, which is notable given its severe price decline, suggesting the moves are driven by company-specific issues rather than amplified market swings.
Beta
0.91
0.91x market volatility
Max Drawdown
-42.8%
Largest decline past year
52-Week Range
$9-$17
Price range past year
Annual Return
-31.2%
Cumulative gain past year
| Period | XRAY Return | S&P 500 |
|---|---|---|
| 1m | +10.1% | -3.6% |
| 3m | -4.0% | +15.3% |
| 6m | -4.4% | +6.1% |
| 1y | -31.2% | +18.6% |
| ytd | -2.3% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
XRAY Fundamental Analysis
Revenue shows modest but positive growth, with Q4 2025 revenue of $961 million representing a 6.19% year-over-year increase; however, this growth is inconsistent quarter-to-quarter, as seen in the sequential decline from $936 million in Q2 2025, and the Technologies & Equipment segment ($548M) is the primary driver, outpacing the Consumables segment ($430M). Profitability is severely challenged, with the company reporting a net loss of -$146 million for Q4 2025 and a gross margin of 46.1%, which compressed from 52.4% in Q2 2025; the operating margin of 6.85% (from valuation data) and a trailing twelve-month net margin of -16.25% highlight ongoing struggles to translate top-line growth into bottom-line results, though the Q4 EBITDA of -$32 million shows some improvement from the -$114 million loss in Q3. The balance sheet carries significant leverage with a debt-to-equity ratio of 1.84, indicating high financial risk, but liquidity is adequate with a current ratio of 1.51; critically, the company generated positive free cash flow of $104 million on a TTM basis and $60 million in Q4 2025, providing a crucial internal funding source for operations and its 5.62% dividend yield, despite the negative ROE of -44.63%.
Quarterly Revenue
$961000000.0B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.46%
Latest Quarter
Free Cash Flow
$104000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is XRAY Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.62, while the Enterprise Value-to-Sales (EV/Sales) is 1.11, indicating the market values the company at a significant discount to its revenue base. Compared to industry averages, which are not provided in the data, a direct peer comparison cannot be quantified; however, a PS ratio below 1.0 typically suggests the market has low expectations for future profitability or growth, which aligns with the company's fundamental challenges. Historically, the stock's own PS ratio has compressed dramatically from levels above 7.0 in early 2024 to the current 0.62, placing it near the very bottom of its multi-year range; this extreme discount reflects deep pessimism and may indicate a value opportunity if the company can demonstrate a credible path to margin recovery, but it also signals the market anticipates continued fundamental deterioration.
PE
-3.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -316x~93x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-96.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe. The company's core risk is its inability to achieve consistent profitability, evidenced by a TTM net margin of -16.25% and a Q4 2025 net loss of -$146 million. High leverage, with a debt-to-equity ratio of 1.84, compounds this risk by increasing fixed obligations. Furthermore, gross margin volatility—compressing from 52.4% in Q2 to 46.1% in Q4—signals potential pricing pressure or cost inefficiencies that could persist, threatening the sustainability of its positive free cash flow ($104M TTM) and its high 5.62% dividend yield.
Market & Competitive Risks center on valuation compression and sector sentiment. Trading at a PS ratio of 0.62, the stock is priced for continued deterioration. A beta of 0.94 indicates its severe underperformance is company-specific, not market-driven, highlighting deep-seated operational issues. The risk is that even if results stabilize, the deeply negative sentiment and lack of analyst coverage (only 5 analysts) could prevent a valuation re-rating, trapping the stock at depressed levels. Competitive pressures in the dental equipment and consumables market could further impede margin recovery.
Worst-Case Scenario involves a failure to stabilize margins, leading to consecutive quarterly losses that erode the positive free cash flow cushion. This could force a dividend cut, triggering further institutional selling, and potentially lead to credit rating downgrades that increase borrowing costs. The realistic downside is a retest and break below the 52-week low of $9.41. Given the stock's 42.79% max drawdown and current price of $9.88, an investor could face a loss of approximately -20% to -25% in a continued adverse scenario, pushing the stock toward the $7.50-$8.00 range if the company's financial position visibly deteriorates.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company has been unable to generate consistent profits, with a TTM net margin of -16.25% and a negative ROE of -44.63%. 2) Financial Leverage Risk: A debt-to-equity ratio of 1.84 increases financial stress and could lead to covenant issues if performance worsens. 3) Dividend Sustainability Risk: The high 5.62% yield is supported by free cash flow today, but a return to negative FCF could force a cut, triggering significant selling. 4) Sentiment & Momentum Risk: The stock is in a persistent downtrend, down 38.63% over the past year, and lacks any positive technical catalysts, which can become a self-fulfilling prophecy.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Base Case (55% probability) sees the stock range-bound between $9.50 and $12.00, as the company muddles through with modest growth but no clear profit recovery. The Bull Case (20% probability), involving a successful turnaround, could drive the stock to $14.00-$17.00. The Bear Case (25% probability), where fundamentals deteriorate further, could see the stock fall to $7.50-$9.40. The most likely scenario is the base case, as it assumes the current challenging status quo—characterized by volatile margins and negative sentiment—persists without a decisive break in either direction.
XRAY is fairly valued relative to its current distressed state, but deeply undervalued relative to a hypothetical recovered version of the company. Its Price-to-Sales ratio of 0.62 and EV/Sales of 1.11 are at crisis levels, reflecting the market's expectation of continued poor profitability (-16.25% net margin). Historically, its own PS ratio has been above 7.0, indicating how far it has fallen. The valuation implies the market has very low expectations for future growth and margin recovery. It is not cheap on an earnings basis because there are no earnings. Therefore, it is fairly valued for a company in a severe operational crisis, but presents potential deep value if a turnaround succeeds.
XRAY is not a good stock to buy for most investors. It is a highly speculative turnaround bet with severe fundamental challenges, including a -16.25% net margin and a 38.63% annual share price decline. The 5.62% dividend yield is attractive but at risk if profitability does not improve. It could be a speculative buy only for deep-value, contrarian investors with a high risk tolerance who believe the extreme valuation discount (PS 0.62) overstates the permanent impairment risk and who are prepared to hold for multiple years awaiting a recovery. For the average investor, the high probability of continued volatility and fundamental disappointment makes it a Hold or Avoid.
XRAY is unsuitable for short-term investment. Its high volatility, lack of positive momentum, and dependence on quarterly earnings reports that have been wildly inconsistent make it a poor trading vehicle. It is only suitable for a very long-term (3-5 year minimum), patient, and speculative investment horizon. This timeframe is necessary to see if management's turnaround efforts can gain traction, stabilize margins, and begin to repair the balance sheet. The high dividend yield may attract income investors, but the risk of a cut makes it unreliable for that strategy. This is purely a capital appreciation bet on a corporate recovery, which will take years to unfold, if it happens at all.